Overcoming Obstacles
Treatment of Agitation Associated With Dementia Due to Alzheimer’s Disease
2024 Alzheimer’s disease facts and figures.
Alzheimer’s Association.
New antipsychotic drugs for the treatment of agitation and psychosis in Alzheimer's disease: focus on brexpiprazole and pimavanserin.
Caraci F, Santagati M, Caruso G, et al. F1000Res. 2020;9:F1000 Faculty Rev-686.
Effect of dextromethorphan-quinidine on agitation in patients with Alzheimer disease dementia: a randomized clinical trial.
Cummings JL, Lyketsos CG, Peskind ER, et al. JAMA. 2015;314(12):1242-1254.
Longitudinal course of agitation and aggression in patients with Alzheimer's disease in a cohort study: methods, baseline and longitudinal results of the A3C study.
De Mauleon A, Delrieu J, Cantet C, et al. J Prev Alzheimers Dis. 2021;8(2):199-209.
Using electronic health records to estimate the prevalence of agitation in Alzheimer disease/dementia.
Halpern R, Seare J, Tong J, et al. Int J Geriatr Psychiatry. 2019;34(3):420-431.
Randomized placebo-controlled trial of nabilone for agitation in Alzheimer's disease.
Herrmann N, Ruthirakuhan M, Gallagher D, et al. Am J Geriatr Psychiatry. 2019;27(11):1161-1173.
Assessment and management of behavioral and psychological symptoms of dementia.
Kales HC, Gitlin LN, Lyketsos CG. BMJ. 2015;350:h369.
The hyperactivity-impulsivity-irritiability-disinhibition-aggression-agitation domain in Alzheimer's disease: current management and future directions.
Keszycki RM, Fisher DW, Dong H. Front Pharmacol. 2019;10:1109.
Brexpiprazole for the treatment of agitation in Alzheimer dementia: a randomized clinical trial.
Lee D, Slomkowski M, Hefting N, et al. JAMA Neurol. 2023;80(12):1307-1316.
Interprofessional insights in agitation in Alzheimer's disease: an interview with the experts from Emory Integrated Memory Care.
Pettis J. Geriatr Nurs. 2024;59:697-700.
Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial.
Porsteinsson AP, Drye LT, Pollock BG, et al. JAMA. 2014;311(7):682-691.
Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease.
Schneider LS, Tariot PN, Dagerman KS, et al. N Engl J Med. 2006;355(15):1525-1538.
Clinical Practice Guidelines
Reduction and prevention of agitation in persons with neurocognitive disorders: an international psychogeriatric association consensus algorithm.
Cummings J, Sano M, Auer S, et al. Int Psychogeriatr. 2024;36(4):251-262.
Agitation in cognitive disorders: progress in the International Psychogeriatric Association consensus clinical and research definition.
Sano M, Cummings J, Auer S, et al. Int Psychogeriatr. 2024;36(4):238-250.
Patient and Caregiver Resources
Alzheimer’s Association
Agitation in Alzheimer’s Screener for Caregivers
Brexpiprazole Prescribing Information
US Food and Drug Administration
Zarit Burden Interview
Overcoming Obstacles
Treatment of Agitation Associated With Dementia Due to Alzheimer’s Disease
| Faculty: | Anton P. Porsteinsson, MD |
| Release: | 11/21/2024 |
| Expiration: | 11/21/2025 |
